News
The company will use the funds to expand nationally, enhance its technology platform and advance clinical innovation.
The company's Dexcom Smart Basal will provide patients with a user-friendly option.
Fabrx's pharmaceutical 3D printing platform is used for research and small batch manufacture of personalized medicine and medical devices.
The funds will be used to expand its direct-to-consumer services and grow partnerships with payers and health systems.
The deal marks Innovaccer's fourth acquisition in the past two years.
The round follows a $200 million seed raise earlier this year.
The company will use the funds to invest in AI research and development initiatives.
The company's AI voice companion allows seniors to engage in conversation via a telephone that does not require additional devices or hardware.
The feature uses machine learning and heart sensor data to flag signs of hypertension and will roll out to Watch Series 9, 10 and 11 as well as Ultra 2 and 3 by month’s end.
Dr. Erik Langhoff, chief medical officer and consultant for the Bronx Regional Health Information Organization, discusses how the agency is addressing safety and efficacy in AI.